An eight-amino-acid cosmetic peptide, a longer Argireline, sold in creams to soften expression lines around the eyes and forehead.
Also called Acetyl octapeptide-3, SNAP-8 peptide
SNAP-8 is a lab-made copy of an eight-amino-acid stretch near the start of SNAP-25, a protein nerve endings need to release the signal that makes a muscle contract. It is Argireline (acetyl hexapeptide-8) with two extra amino acids added. The idea is that the decoy slips into the release machinery and weakens it a little, so the small muscles that crease the skin around the eyes and forehead pull less. Botox works on the same machinery, but by cutting SNAP-25 outright.
The human evidence for SNAP-8 itself is thin. The supplier reported that women using a cream with 10% of its SNAP-8 ingredient had up to 63% less wrinkle depth after 28 days, but that test was never published as a peer-reviewed paper and the sample size and placebo details are not public. The two peer-reviewed human studies that include SNAP-8 used microneedle patches that also contained other active ingredients, so the peptide's own effect cannot be separated out.
Its parent, Argireline, has somewhat better data, including a 60-person placebo-controlled trial. Even so, a 2025 review concluded it is still unclear whether these peptides reach the nerve-muscle junction from the skin surface. SNAP-8 is a cosmetic ingredient, not a drug, and injecting it is untested.
What it binds to, and what happens inside the body after that, step by step.
To fire a muscle, a nerve ending fuses small sacs of acetylcholine with its outer membrane using a three-protein clamp called the SNARE complex, and SNAP-25 is one of those proteins. SNAP-8 copies a short stretch of SNAP-25 and is meant to compete for its place in the clamp, so some clamps form badly and less signal gets released. Lab tests showing reduced neurotransmitter release were done on its parent, Argireline; whether enough peptide gets through the skin to do this in facial muscles is not established.
Human results and animal results are kept apart below. A result in rats tells you a mechanism is plausible. It does not tell you what happens in a person.
For SNAP-8 itself, the only human data are an unpublished supplier test and two small microneedle-patch studies where it was mixed with other actives. Its parent peptide, Argireline, has one 60-person placebo-controlled trial showing fewer eye wrinkles after 4 weeks, but no study shows these peptides reach facial muscles through intact skin.
Women volunteers, sample size not reported
A cream with 10% SNAP-8 ingredient gave up to 63% maximum wrinkle depth reduction after 28 days; this is supplier data without peer review or published placebo details.
Read the study24 healthy adults, active patch on one eye area and plain hyaluronic acid patch on the other
The patch with acetyl octapeptide-3 plus a vitamin C derivative and lysophosphatidic acid improved eye wrinkles more than the plain patch over 28 days, with no adverse effects.
Read the studyHealthy adults with aged skin, 12 weeks
A patch combining acetyl octapeptide-3 with four other ingredients (an arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts) reduced fine lines by 25.8% and raised dermal density 14.2%, with no control arm to isolate the peptide.
Read the study60 adults with periorbital wrinkles (3:1 Argireline to placebo)
Overall anti-wrinkle efficacy was 48.9% with Argireline versus 0% with placebo after 4 weeks of twice-daily use; this tested the parent peptide, not SNAP-8.
Read the studyLab neurosecretion assays plus healthy women volunteers
Argireline blocked neurotransmitter release in lab assays, and a 10% emulsion reduced wrinkle depth by up to 30% after 30 days in volunteers.
Read the studyPurified SNARE proteins, permeabilized cells and cultured hippocampal neurons
Peptides copying the SNAP-25 N-terminus blocked SNARE complex formation and calcium-triggered release, which is the mechanism SNAP-8 is built on.
Read the studyThese are questions the published research has not answered.
No product containing SNAP-8 is approved as a medicine by the FDA.
Sold in topical cosmetics, which FDA does not review for efficacy before sale. It is not an approved drug anywhere and has no drug development program. The US Cosmetic Ingredient Review panel assessed the parent peptide, Argireline (acetyl hexapeptide-8 amide), in 2025 and found it safe only up to 0.005% in cosmetics, saying data were insufficient above that; SNAP-8 itself has no published CIR assessment. Not named on the WADA list.
No human half-life has been published for SNAP-8, so we do not draw a clearance curve. Half-lives quoted online for it are usually estimates from animal data.
This table records the doses that trials and approved labels used, with the source for each row. It is a record of research, not a recommendation, and it is open to free members.
Which symptoms are expected and which mean stop and get help: side effects and red flags.
Tap a claim to see what the studies found.
Both act on SNAP-25, but Botox cuts the protein inside the nerve and lasts months. SNAP-8 is a weak competitor applied to the skin surface, and no study shows effects anywhere near Botox.
That number is the maximum reduction reported in a supplier test that was never peer-reviewed and has no public sample size or placebo comparison.
The supplier says so, but no independent head-to-head trial has been published.
Nobody has studied injected SNAP-8. Injecting cosmetic peptides adds real infection risk, as a published Argireline injection case showed.
These pairings come up often. Almost none have been tested together in a trial, and the evidence note on each says so plainly.
Sold mainly as a pre-dissolved cosmetic ingredient; no drug-grade storage guidance exists.
Follow the cosmetic product's packaging and expiry date; no independent stability data are published.
One email when a trial reads out, a label changes or the FDA acts on a peptide. Free, no selling of peptides, unsubscribe any time.